|
|
|
|
| LEADER |
04276nma a2201189 u 4500 |
| 001 |
EB002143810 |
| 003 |
EBX01000000000000001281936 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
230202 ||| eng |
| 020 |
|
|
|a 9783036553528
|
| 020 |
|
|
|a books978-3-0365-5351-1
|
| 020 |
|
|
|a 9783036553511
|
| 100 |
1 |
|
|a Mordon, Serge
|
| 245 |
0 |
0 |
|a Photodynamic Therapy 2021
|h Elektronische Ressource
|
| 260 |
|
|
|a Basel
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2022
|
| 300 |
|
|
|a 1 electronic resource (238 p.)
|
| 653 |
|
|
|a resistance
|
| 653 |
|
|
|a radiation therapy
|
| 653 |
|
|
|a fluorescent dyes
|
| 653 |
|
|
|a magnetic nanoparticles
|
| 653 |
|
|
|a dALA
|
| 653 |
|
|
|a bacteria
|
| 653 |
|
|
|a tin complex
|
| 653 |
|
|
|a photoantimicrobial chemotherapy
|
| 653 |
|
|
|a prophylactic treatment
|
| 653 |
|
|
|a U251
|
| 653 |
|
|
|a methylene blue
|
| 653 |
|
|
|a skin tumors
|
| 653 |
|
|
|a Oncology / bicssc
|
| 653 |
|
|
|a chitosan
|
| 653 |
|
|
|a MDR
|
| 653 |
|
|
|a protoporphyrin IX
|
| 653 |
|
|
|a SSTI
|
| 653 |
|
|
|a talaporfin sodium
|
| 653 |
|
|
|a programmed death-ligand 1 protein (PD-L1)
|
| 653 |
|
|
|a peptide-imprinted polymer
|
| 653 |
|
|
|a dental implant
|
| 653 |
|
|
|a clinical trials
|
| 653 |
|
|
|a PpIX
|
| 653 |
|
|
|a immunotherapy
|
| 653 |
|
|
|a photodynamic therapy
|
| 653 |
|
|
|a riboflavin
|
| 653 |
|
|
|a glioblastoma
|
| 653 |
|
|
|a absorption
|
| 653 |
|
|
|a Photofrin®
|
| 653 |
|
|
|a 5-ALA
|
| 653 |
|
|
|a ultraviolet radiation
|
| 653 |
|
|
|a singlet oxygen
|
| 653 |
|
|
|a photosensitizing agents
|
| 653 |
|
|
|a AGuIX®
|
| 653 |
|
|
|a incubation time
|
| 653 |
|
|
|a PDT
|
| 653 |
|
|
|a zinc (II) phthalocyanine
|
| 653 |
|
|
|a photochemistry
|
| 653 |
|
|
|a methyl aminolevulinate
|
| 653 |
|
|
|a curcumin
|
| 653 |
|
|
|a cross-linking agents
|
| 653 |
|
|
|a illumination time
|
| 653 |
|
|
|a photoinactivation
|
| 653 |
|
|
|a pyropheophorbide-a
|
| 653 |
|
|
|a murine models
|
| 653 |
|
|
|a melanoma
|
| 653 |
|
|
|a gadolinium
|
| 653 |
|
|
|a natural photosensitizer
|
| 653 |
|
|
|a decontamination
|
| 653 |
|
|
|a fluorescence
|
| 653 |
|
|
|a peri-implantitis
|
| 653 |
|
|
|a protein conformation
|
| 653 |
|
|
|a squamous cell carcinoma
|
| 653 |
|
|
|a laser
|
| 653 |
|
|
|a normal keratinocytes
|
| 653 |
|
|
|a chemotherapy
|
| 653 |
|
|
|a terbium
|
| 653 |
|
|
|a skin cancer treatment
|
| 653 |
|
|
|a liposomes
|
| 653 |
|
|
|a immune checkpoint inhibition
|
| 653 |
|
|
|a β-mannose-conjugated chlorin e6
|
| 653 |
|
|
|a Rose Bengal
|
| 653 |
|
|
|a ceramics
|
| 653 |
|
|
|a δALA
|
| 653 |
|
|
|a hairless mice
|
| 653 |
|
|
|a glioblastoma multiforme
|
| 653 |
|
|
|a X-ray-induced photodynamic therapy
|
| 653 |
|
|
|a actinic keratosis
|
| 653 |
|
|
|a Medicine and Nursing / bicssc
|
| 653 |
|
|
|a photothermal therapy
|
| 653 |
|
|
|a antimicrobial agents
|
| 653 |
|
|
|a oxidation reduction
|
| 653 |
|
|
|a 5-aminolevulinic acid
|
| 700 |
1 |
|
|a Mordon, Serge
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 024 |
8 |
|
|a 10.3390/books978-3-0365-5351-1
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/6212
|7 0
|x Verlag
|3 Volltext
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/93784
|z DOAB: description of the publication
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 580
|
| 082 |
0 |
|
|a 540
|
| 082 |
0 |
|
|a 700
|
| 520 |
|
|
|a Photodynamic therapy (PDT) is a light-based photochemistry process. The illumination of a photoactivatable molecule (also called photosensitizer) with visible or near infrared light produces reactive oxygen toxic species to destroy tumor cells. This treatment modality leads to highly targeted actions, because reactive oxygen species are produced only where light is applied. Light is not harmful, nor is the photoactivable molecule. Only the combination of three elements (photosensitizer, oxygen, and light) is required to induce photo-oxidation reactions. PDT has proven to be a promising modality in many medical applications including cutaneous condition, infectious diseases, and various cancers at different stages. This book is a reprint of the Special Issue "Photodynamic Therapy 2021" that was published in Pharmaceuticals.
|